Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PAS-003 is a dual-targeting chimeric antigen receptor (CAR) T-cell therapy being developed by Porton Advanced for the treatment of acute myeloid leukemia (AML). The therapy involves engineering T cells to express CARs that simultaneously recognize Natural Killer Group 2D ligands (NKG2DL) and CD33, both of which are frequently overexpressed on leukemic blasts and leukemic stem cells. By targeting two distinct antigens, PAS-003 aims to enhance the specificity and efficacy of the treatment while potentially reducing the risk of antigen escape, a common mechanism of resistance in single-target CAR-T therapies. The drug is currently in the preclinical stage of development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PAS-003 (Porton Advanced).